Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPTTM Blood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience. - Centre de Recherche en Cancérologie de Marseille Accéder directement au contenu
Article Dans Une Revue Blood transfusion = Trasfusione del sangue Année : 2023

Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPTTM Blood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience.

Résumé

The INTERCEPTTM Blood System (Intercept Blood System, Cerus Europe BV, Amersfoort, the Netherlands) has been used to reduce or inactivate pathogen load in platelet concentrates in France for three years.
Fichier non déposé

Dates et versions

hal-03996550 , version 1 (20-02-2023)

Identifiants

Citer

Patrick Ladaique, Jean-Michel Etienne, Pascal Pedini, Jacques Chiaroni, Norbert Vey, et al.. Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPTTM Blood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience.. Blood transfusion = Trasfusione del sangue, 2023, ⟨10.2450/2023.0143-22⟩. ⟨hal-03996550⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More